-
P647559-5mgPD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC 50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor
-
P655084-1mlPD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC 50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor
-
P659048-10mgPD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC 50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride
-
P659048-25mgPD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC 50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride
-
P659048-5mgPD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC 50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride
-
P651382-100mgPD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC 50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effectsIn VitroPD-1/PD-L1-IN-NP19
-
P651382-10mgPD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC 50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effectsIn VitroPD-1/PD-L1-IN-NP19
-
P651382-25mgPD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC 50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effectsIn VitroPD-1/PD-L1-IN-NP19
-
P651382-50mgPD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC 50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effectsIn VitroPD-1/PD-L1-IN-NP19
-
P651382-5mgPD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC 50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effectsIn VitroPD-1/PD-L1-IN-NP19
-
P656651-1mlPD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC 50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effectsIn VitroPD-1/PD-L1-IN-NP19
-
P659082-10mgPD-L1-IN-1 is a potent PD-L1 inhibitor with an IC 50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells (PC9 and HCC827 cells) and peripheral blood mononuclear cells